Li Weng

机构：Zhujiang Hospital · ORCID：0009-0000-6080-7488

发表论文 48 篇 · 总被引 1535 次 · h-index 16

代表论文

• Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma (2015 · JAMA Oncology · 被引 310)
• Functional characterization of uveal melanoma oncogenes (2020 · Oncogene · 被引 76)
• A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphoma (2016 · British Journal of Haematology · 被引 69)
• Ginsenoside Rh1 potentiates dexamethasone’s anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance (2014 · Arthritis Research & Therapy · 被引 42)
• CLAmp‐seq: A Novel Amplicon‐Based NGS Assay with Concatemer Error Correction for Improved Detection of Actionable Mutations in Plasma cfDNA from Patients with NSCLC (2019 · Small Methods · 被引 27)
• N6-methyladenosine methylation mediates non-coding RNAs modification in microplastic-induced cardiac injury (2023 · Ecotoxicology and Environmental Safety · 被引 24)